SCHEMBL1973802

SCHEMBL1973802

COC(=O)c1cc(NC(C)=O)c([N+](=O)[O-])cc1OC(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 2/20 0.48
GALR2 O43603 1/20 0.48
MITF O75030 1/20 0.48
LMNA P02545 1/20 0.48
HSP90AA1 P07900 1/20 0.48
HPGD P15428 1/20 0.48
XBP1 P17861 1/20 0.48
CCR6 P51684 1/20 0.48
KMT2A Q03164 2/20 0.44
MAPT P10636 2/20 0.42
HTT P42858 4/20 0.40
PDGFRB P09619 1/20 0.38
FGFR1 P11362 1/20 0.38
PDGFRA P16234 1/20 0.38
FLT1 P17948 1/20 0.38
FGFR3 P22607 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9527341 0.87 LMNA (0.48) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL12215941 0.86 LMNA (0.50) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL9528380 0.85 LMNA (0.44) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL9527822 0.84 NPSR1 (0.45) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL9687916 0.84 LMNA (0.48) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL8954112 0.83 SMN1; SMN2 (0.58) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL1727258 0.81 ALDH1A1 (0.53) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL31575929 0.80 PDGFRB (0.43) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL2554500 0.79 KMT2A (0.55) NPSR1SMN1; SMN2ALDH1A1POLBGALR2
SCHEMBL31575934 0.78 KMT2A (0.42) NPSR1SMN1; SMN2ALDH1A1POLBGALR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040565-B2 1H-benzimidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2015-05-26 US disclosed
US-20120122930-A1 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-17 US disclosed
EP-2334664-A1 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP disclosed
WO-2010034797-A1 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122930-A1 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, MAP4 NPSR1 2775/4885SMN1; SMN2 3372/4885ALDH1A1 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.